Sarepta Therapeutics, Inc. (FRA:AB3A)

Market Cap	1.83B -58.3%
Revenue (ttm)	1.87B +15.6%
Net Income	-607.61M
EPS	-6.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	4.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	61
Open	17.10
Previous Close	16.86
Day's Range	17.10 - 17.10
52-Week Range	8.96 - 55.82
Beta	n/a
RSI	48.84
Earnings Date	May 6, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 835
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AB3A

Financial Performance

Financial numbers in USD